Last updated on October 2016

NN2211-4232 LIRA-PRIME: Efficacy in controlling glycaemia with Victoza (liraglutide) as add-on to metformin vs. OAD's as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting.


Brief description of study

NN2211-4232 LIRA-PRIME: Efficacy in controlling glycaemia with Victoza (liraglutide) as add-on to metformin vs. OAD's as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting.

Detailed Study Description

A 104 week randomized, phase 4, open-label, active-controlled, multicenter, multinational, parallel-group trial.

Clinical Study Identifier: TX145559

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.